ESR1 c.307_309delinsTGT ;(p.V103C)

Variant ID: 6-152129354-GTG-TGT

NM_000125.3(ESR1):c.307_309delinsTGT;(p.V103C)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.

Oncotarget
Liu, Chun-Yu CY; Hu, Ming-Hung MH; Hsu, Chia-Jung CJ; Huang, Chun-Teng CT; Wang, Duen-Shian DS; Tsai, Wen-Chun WC; Chen, Yi-Ting YT; Lee, Chia-Han CH; Chu, Pei-Yi PY; Hsu, Chia-Chi CC; Chen, Ming-Huang MH; Shiau, Chung-Wai CW; Tseng, Ling-Ming LM; Chen, Kuen-Feng KF
Publication Date: 2016-02-23

Variant appearance in text: ER-alpha: V103C
PubMed Link: 26824320
Variant Present in the following documents:
  • Main text
  • oncotarget-07-9135.pdf
View BVdb publication page



Screening to Identify Commonly Used Chinese Herbs That Affect ERBB2 and ESR1 Gene Expression Using the Human Breast Cancer MCF-7 Cell Line.

Evidence-Based Complementary And Alternative Medicine : Ecam
Chiu, Jen-Hwey JH; Chang, Chun-Ju CJ; Wu, Jing-Chong JC; Liu, Hui-Ju HJ; Wen, Che-Sheng CS; Hsu, Chung-Hua CH; Chen, Jiun-Liang JL; Tseng, Ling-Ming LM; Chen, Wei-Shone WS; Shyr, Yi-Ming YM
Publication Date: 2014

Variant appearance in text: ESR1: V103C
PubMed Link: 24987437
Variant Present in the following documents:
  • Main text
  • ECAM2014-965486.pdf
View BVdb publication page